http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2400149-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10efc646a4dd605c2f09c493718f5b81 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B10-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate | 2009-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2010-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaa2a58884999736778c663ecbf0d5fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_809a121afe8414ce3e648dfec4dd3938 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c499ba5990c2e862b9fd62cb2eced8d3 |
publicationDate | 2010-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2400149-C1 |
titleOfInvention | Differential diagnostic technique of round pulmonary shadows in patients with chronic obstructive pulmonary disease |
abstract | FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to pulmonology. The patient's blood is analysed for CD3+ CD 16-, CD19+CD23+, CD45RA+CD4+/CD45RO+CD4+, a zymozan stimulated nitro blue tetrazolium test (NBT-induced test), a nitro blue tetrazolium reduction test (NBT-spontaneous test), a phytohemagglutinin response are carried out. If CD3+CD16- exceeds 1.85*10^3, CD45RA+CD4+/CD45RO+CD4+ is lower than 0.85, NBT-induced test is higher than 38%, lung cancer is diagnosed. The values CD19+CD23+ lower than 0.07*10^3, phytohemagglutinin response lower than 2.1, NBT-spontaneous test lower than 7% indicate lung abscess. ^ EFFECT: technique allows for precise differentiation of said diseases; it is safe and technologically feasible. ^ 2 ex |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2585385-C2 |
priorityDate | 2009-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.